{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:49:09Z","timestamp":1784630949529,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"crossref","award":["223273"],"award-info":[{"award-number":["223273"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"crossref","award":["FPU12\/01827"],"award-info":[{"award-number":["FPU12\/01827"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.euroneuro.2015.03.002","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T12:54:20Z","timestamp":1427288060000},"page":"923-932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain"],"prefix":"10.1016","volume":"25","author":[{"given":"J.","family":"Fern\u00f8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Ersland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.H.","family":"Duus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.O.","family":"Fossan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.M.","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.03.002_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/mp.2010.33","article-title":"Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis","volume":"16","author":"Albaugh","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2015.03.002_bib3","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/schbul\/sbq053","article-title":"Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents","volume":"38","author":"Albaugh","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.euroneuro.2015.03.002_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/JCP.0b013e318166c4f7","article-title":"Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions","volume":"28","author":"Birkenaes","year":"2008","journal-title":"J. Clin. Psychopharm."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.03.002_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","author":"Brown","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1194\/jlr.M026948","article-title":"Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro","volume":"54","author":"Canfran-Duque","year":"2013","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.002_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.002_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0269881106069637","article-title":"Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities","volume":"21","author":"Cooper","year":"2007","journal-title":"J. Psychopharmacol."},{"issue":"16","key":"10.1016\/j.euroneuro.2015.03.002_bib12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2015.03.002_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","article-title":"Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study","volume":"105","author":"Daumit","year":"2008","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FBP.0b013e3282f62c66","article-title":"Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat","volume":"19","author":"Davoodi","year":"2008","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","article-title":"The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats","volume":"194","author":"Fell","year":"2007","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.03.002_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.tpj.6500323","article-title":"Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?","volume":"5","author":"Ferno","year":"2005","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"Ferno","year":"2009","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.03.002_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archgenpsychiatry.2011.2","article-title":"Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis","volume":"68","author":"Foley","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.03.002_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00210-013-0933-5","article-title":"Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects","volume":"387","author":"Girault","year":"2014","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.002_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2009.09.032","article-title":"Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance","volume":"207","author":"Guesdon","year":"2010","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-002-1368-8","article-title":"Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat","volume":"167","author":"Hartfield","year":"2003","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.03.002_bib24","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/sj.npp.1300949","article-title":"Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats","volume":"31","author":"Hartfield","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.002_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00213-011-2397-y","article-title":"Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat","volume":"219","author":"Jassim","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.03.002_bib26","first-page":"CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.002_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.euroneuro.2015.03.002_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archgenpsychiatry.2009.61","article-title":"Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder","volume":"66","author":"Laursen","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.03.002_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.euroneuro.2015.03.002_bib30","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2011.03.016","article-title":"Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity","volume":"129","author":"McNamara","year":"2011","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.002_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.appet.2006.01.008","article-title":"Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration","volume":"46","author":"Minet-Ringuet","year":"2006","journal-title":"Appetite"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbr.2005.05.004","article-title":"Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection","volume":"163","author":"Minet-Ringuet","year":"2005","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.002_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00213-006-0433-0","article-title":"A model for antipsychotic-induced obesity in the male rat","volume":"187","author":"Minet-Ringuet","year":"2006","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2015.03.002_bib35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.schres.2008.09.002","article-title":"Changes in non-high-density lipoprotein cholesterol levels and triglyceride\/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine","volume":"106","author":"Newcomer","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib36","doi-asserted-by":"crossref","first-page":"e55176","DOI":"10.1371\/journal.pone.0055176","article-title":"Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden","volume":"8","author":"Nordentoft","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archpsyc.64.2.242","article-title":"Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom\u05f3s general practice rsearch database","volume":"64","author":"Osborn","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2015.03.002_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","article-title":"Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human","volume":"75","author":"Pouzet","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2015.03.002_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-006-9160-4","article-title":"SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?","volume":"289","author":"Raeder","year":"2006","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1520\/JFS14697J","article-title":"Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic?","volume":"45","author":"Robertson","year":"2000","journal-title":"J. Forensic Sci."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2015.03.002_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"17\u201318","key":"10.1016\/j.euroneuro.2015.03.002_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.lfs.2011.02.014","article-title":"Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats","volume":"88","author":"Shobo","year":"2011","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib44","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbr.2010.08.046","article-title":"Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone","volume":"216","author":"Shobo","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145713000862","article-title":"Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects","volume":"17","author":"Skrede","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.002_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1194\/jlr.E034736","article-title":"Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition?","volume":"54","author":"Skrede","year":"2013","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.002_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain","volume":"17","author":"Stefanidis","year":"2009","journal-title":"Obesity"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.03.002_bib49","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2015.03.002_bib50","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men","author":"Vidarsdottir","year":"2009","journal-title":"J. Clin. Endocrinol. Metab"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:53:55Z","timestamp":1760378035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0924977X15000784"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}